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 Metalloproteinases �MMPs�� are gro�p of enzymes 
that play significant role in the metabolism of extracell�lar 
matrix components�� tiss�e repair and cell migration [�]. 
MMPs are secreted in inactive form from different kind 
of cells or are expressed as plasma membrane bo�nd 
form. MMPs play important roles in t�mor invasion and 
metastasis and are also involved in initial stages of t�mor 
development by reg�lating cell proliferation�� apoptosis�� 
angiogenesis and imm�ne s�rveillance [��� 3]. Matrix 
metalloproteinase-� �MMP-��� belongs to the family of 
gelatinases that occ�py special position beca�se of their 
ability to degrade both elastin and type IV collagen — ma-
jor component of basal membrane [4�� 5].
L�ng cancer�� the leading cancer type in the developed 
co�ntries�� has been widely investigated for its etiological 
factors. Some nat�ral genetic variations have been as-
sociated with individ�al s�sceptibility to this t�mor [��� �]. 
More than one million new ca�ses of l�ng cancer occ�r in 
the world every year. Non-small cell l�ng cancer �NSCLC�� 
acco�nts more than �5% of l�ng cancers.
Elevation of MMP-� level associated with metas-
tasis and with decrease of s�rvival time�� has been 
reported [����]. The aim of this st�dy was to inves-
tigate the interaction between the levels of MMP-� 
in broncho-alveolar lavage fl�id �BALF�� and plasma 
of patients with NSCLC and to analize correlation bet-
ween these indices and t�mor stage.
Blood plasma samples from 4� healthy donors 
��� males and �� females�� and 4� NSCLC patients �3� 
males and � females�� c�red in Ankara N�m�ne Teach-
ing and Research Hospital �T�rkey�� from March ���4 
to April ���5�� were st�died. The mean age of NSCLC 
patients and controls was 5� ± �.3 years �range 3������ 
and 54 ± ��.� years �range 34������� respectively. Based 
on the WHO criteria�� the patients gro�p consisted of 
�4 patients with adenocarcinoma and �� with sq�a-
mo�s cell carcinoma. Nineteen patients had early 
stage of disease �� patients with stage I and �3 patients 
with stage II���� �3 patients had locally advanced disease 
�stage III���� � patients were at stage IV. All patients were 
staged at the time of s�rgery following the g�idelines 
of the American �oint Committee on Cancer Stag-
ing [��]. The proced�re incl�ded chest radiography�� 
comp�ter tomography �CT�� scans of the chest and 
abdomen�� magnetic resonance imaging of the brain 
and bone scanning. Local ethical committee approved 
all protocols for this st�dy. Patients with NSCLC and 
healthy donors were smokers. Clinical parameters of 
patients are s�mmarized in Table �.
Table 1. Clinicopathologic parameters of patients with NSCLC
Parameters NSCLC patients (n = 40)
Age (years)
Mean
Range
56 ± 8.3
31–71
Gender
Male
Female
32
8
Histological Type
Adenocarcinoma
Squamous cell carcinoma
14
26
Stage
IA
IB
IIA
IIB
IIIA
IIIB
IV
1
5
4
9
9
4
8
BALF were collected only from the gro�p of pa-
tients with NSCLC. Veno�s blood samples obtained 
from NSCLC patients and donors were placed in t�bes 
containing EDTA�� immediately centrif�ged ��5�� g x 
�� min��. BALF and plasma were stored in aliq�ots at 
��� °C �ntil �se.
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ELISA was performed to detect MMP-� in ser�m and 
BALF samples�� �sing Q�antikine kits �R & D Systems 
Inc.�� Minneapolis�� USA�� and specific antibodies by 
ro�tine proced�re. The optical density was detected 
�sing Tecan S�nrise Elisa Microplate Reader �UK�� at 
wave length of 45� nm. Each sample was assayed in 
d�plicate and val�es were within the linear portion of the 
standard c�rve. The minim�m detectable concentration 
was less than �.�5� ng/ml. 
Val�es were expressed as Mean ± SE. The dif-
ference between gro�ps was eval�ated by St�dents 
t-test. The difference between stages was meas�red 
by Kr�skall-Wallis and than Mann Whitney U-test. For 
correlation analysis Pearsons test was �sed. The dif-
ference was considered significant if p < �.��.
The plasma MMP-� level of NSCLC patients 
����.�� ± ���.�� ng/ml�� was significantly higher than in 
control gro�p ����.�� ± ��.�� ng/ml�� p < ���������. Level 
of BALF MMP-� was determined in NSCLC patients 
��55.�� ± ���.3� ng/ml��. Level of plasma MMP-� from 
patients with stage IV was significantly higher than in 
controls �Table ���.
Table 2. Levels of plasma and BALF MMP-9 in patients with NSCLC.
Sex F/M Hystologic Type A/S
Plasma MMP-9 
ng/ml BALF MMP-9 ng/ml
Stage I 1/5 1/5 176.5 ± 90.95* 412.17 ± 108.84**
Stage II 4/9 5/8 198.38 ± 86.98 636.15 ± 334.45
Stage III 3/10 6/7 211.69 ± 83.11 780.34 ± 387.71
Stage IV 0/8 2/6 560.62 ± 220.25* 1667.62 ± 754.04**
Control 11/29 — 118.80 ± 97.17 —
Female/Male F/M, Adenocarcinoma/Squamous cell carcinoma A/S
*p < 0.005 stage I–IV plasma MMP-9 levels
**p < 0.002 stage I–IV BALF MMP-9 levels
Plasma and BALF MMP-� levels in stages I patients 
were significantly lower than these in stages IV patients 
�p < �.��� and p < �.��5�� respectively��. MMP-� levels in 
BALF were similar at early stages�� b�t that in stage IV was 
characterized by the highest level of BALF and plasma 
MMP-� levels �stage I vs stage IV — p < �.����� stage II vs 
stage IV — p < �.����� and stage III vs stage IV — p < �.��� 
for BALF; stage I vs IV — p < �.��5�� stage II vs IV — p < �.���� 
and stage III vs IV — p < �.�� for plasma MMP-���. 
The correlation between MMP-� level in blood 
plasma or BALF and the stage of disease was fo�nd 
significant �Pearson’s r = �.��� �p < �.�������� Pear-
son’s r = �.�3� �p < �.������ respectively��. However�� 
no correlation between plasma or BALF MMP-� levels 
and gender �r = �.�3� for plasma�� r = �.3�� for BALF�� 
p > �.�5���� or histological type of t�mor �r = �.��� for 
plasma�� r = �.��� for BALF�� has been revealed. 
So�� o�r st�dy has demonstrated the significant in-
crease of plasma MMP-� level in NSCLC patients com-
pared to healthy donors. This finding is in accordance with 
the data of other a�thors [��� ���� �3�� �4] reporting on eleva-
tion of plasma or ser�m MMP-� levels in NSCLC patients. 
In agreement with previo�s reports [�5�� ��]�� o�r res�lts 
showed that MMP-� levels do not depend significantly on 
patient’s gender or/and histological type of t�mor. 
We report for the first time an association between 
BALF MMP-� levels and stage of NSCLC. The levels 
of BALF MMP-� are increased �pon advanced l�ng 
cancer�� however the mechanisms responsible for the 
elevation of MMP-� levels remain �nclear. F�rther 
st�dies on a larger n�mber of patients are req�ired to 
explore the prognostic val�es for these metastasis-
associated markers for NSCLC.
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Содержание матрикСной метаЛЛоПротеинаЗЫ 9 
в БронХоаЛЬвеоЛЯрной жидкоСти БоЛЬнЫХ 
немеЛкокЛетоЧнЫм раком ЛеГкоГо 
Цель: определить концентрацию матриксной металлопротеиназы 9 (ММП-9) в плазме крови и бронхо-альвеолярной 
жидкости (БАЖ) больных немелкоклеточным раком легкого (НМКРЛ). Методы: концентрацию ММП-9 в плазме крови 
и БАЖ больных НМКРЛ (n �� 40) и здоровых доноров (n �� 40) определяли имм�но�ерментным методом и анализировали              
корреляцию этих параметров с клиническими данными (полом больного, гистологическим типом оп�холи, стадией забо-
левания). Результаты: содержание ММП-9 в плазме крови было значительно выше � больных НМКРЛ по сравнению с 
контрольной гр�ппой (p < 0,0001), особенно � больных с IV стадией заболевания. �тадия IV НМКРЛ также характери-       
зовалась наиболее высоким �ровнем ММП-9 в БАЖ. Корреляции межд� �ровнем ММП-9 в плазме крови и БАЖ, полом 
больного и гистологическим типом оп�холи не была выявлена. Выводы: с�ществ�ет статистически значимая корреляция 
межд� стадией развития НМКРЛ и содержанием ММП-9 в плазме крови и БАЖ больных.
Ключевые слова: матриксная металлопротеиназа 9, плазма крови, бронхо-альвеолярная жидкость, немелкоклеточный 
рак легкого, метастазы, гистологический тип оп�холи.
Copyright © Experimental Oncology, 2006
